DOP2024000076A - Compuestos y métodos dirigidos a la interleucina-34 - Google Patents
Compuestos y métodos dirigidos a la interleucina-34Info
- Publication number
- DOP2024000076A DOP2024000076A DO2024000076A DO2024000076A DOP2024000076A DO P2024000076 A DOP2024000076 A DO P2024000076A DO 2024000076 A DO2024000076 A DO 2024000076A DO 2024000076 A DO2024000076 A DO 2024000076A DO P2024000076 A DOP2024000076 A DO P2024000076A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methods
- targetting
- interleukin
- compounds
- antibodies
- Prior art date
Links
- 102100033499 Interleukin-34 Human genes 0.000 title abstract 2
- 101710181549 Interleukin-34 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 | |
| PCT/US2022/078776 WO2023076995A1 (en) | 2021-10-29 | 2022-10-27 | Compounds and methods targeting interleukin-34 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000076A true DOP2024000076A (es) | 2024-06-16 |
Family
ID=84367272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000076A DOP2024000076A (es) | 2021-10-29 | 2024-04-26 | Compuestos y métodos dirigidos a la interleucina-34 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (enExample) |
| EP (1) | EP4423127A1 (enExample) |
| JP (3) | JP7622019B2 (enExample) |
| KR (1) | KR20240099349A (enExample) |
| CN (1) | CN118475610A (enExample) |
| AR (1) | AR127484A1 (enExample) |
| AU (1) | AU2022376940A1 (enExample) |
| CA (1) | CA3236555A1 (enExample) |
| CL (1) | CL2024001303A1 (enExample) |
| CO (1) | CO2024005417A2 (enExample) |
| CR (1) | CR20240170A (enExample) |
| DO (1) | DOP2024000076A (enExample) |
| EC (1) | ECSP24032906A (enExample) |
| IL (1) | IL312380A (enExample) |
| MX (1) | MX2024005153A (enExample) |
| PE (1) | PE20241471A1 (enExample) |
| TW (1) | TW202336034A (enExample) |
| WO (1) | WO2023076995A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240145486A (ko) * | 2022-02-03 | 2024-10-07 | 일라이 릴리 앤드 캄파니 | 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028427B1 (ru) | 2008-07-21 | 2017-11-30 | Пробиодруг Аг | АНТИТЕЛО, СВЯЗЫВАЮЩЕЕСЯ С Aβ-ПЕПТИДАМИ ИЛИ ИХ ВАРИАНТАМИ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО, И ЕГО ПРИМЕНЕНИЕ |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| PT3042917T (pt) | 2010-08-12 | 2018-05-02 | Lilly Co Eli | Anticorpos do péptido beta amilóide anti-n3pglu e seus usos |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| EP3174895A1 (en) | 2014-07-28 | 2017-06-07 | Nogra Pharma Limited | Methods and compositions for diagnosing and treating inflammatory bowel disorders |
| WO2016097420A1 (en) | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
| AU2016248946C1 (en) * | 2015-04-13 | 2024-10-17 | Pfizer Inc. | Therapeutic antibodies and their uses |
| JP2018516933A (ja) * | 2015-06-02 | 2018-06-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN109562167A (zh) * | 2016-08-09 | 2019-04-02 | 伊莱利利公司 | 联合治疗 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| CA3091810A1 (en) | 2018-03-02 | 2019-09-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of il-34 to treat retinal inflammation and neurodegeneration |
| BR112021021062A2 (pt) | 2019-05-31 | 2021-12-14 | Lilly Co Eli | Compostos e métodos que alvejam tau humano |
| TWI799840B (zh) * | 2020-04-30 | 2023-04-21 | 美商美國禮來大藥廠 | 靶向介白素-34之化合物及方法 |
-
2022
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118475610A (zh) | 2024-08-09 |
| KR20240099349A (ko) | 2024-06-28 |
| US20240309082A1 (en) | 2024-09-19 |
| JP2023067832A (ja) | 2023-05-16 |
| CL2024001303A1 (es) | 2024-08-30 |
| JP2025063187A (ja) | 2025-04-15 |
| IL312380A (en) | 2024-06-01 |
| TW202336034A (zh) | 2023-09-16 |
| WO2023076995A1 (en) | 2023-05-04 |
| US11976114B2 (en) | 2024-05-07 |
| CO2024005417A2 (es) | 2024-05-30 |
| JP2024091777A (ja) | 2024-07-05 |
| PE20241471A1 (es) | 2024-07-17 |
| AR127484A1 (es) | 2024-01-31 |
| US20230279094A1 (en) | 2023-09-07 |
| CA3236555A1 (en) | 2023-05-04 |
| AU2022376940A1 (en) | 2024-05-02 |
| EP4423127A1 (en) | 2024-09-04 |
| ECSP24032906A (es) | 2024-05-31 |
| MX2024005153A (es) | 2024-05-13 |
| CR20240170A (es) | 2024-05-24 |
| JP7622019B2 (ja) | 2025-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22084245A (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| CO2022013274A2 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| ECSP20075198A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| CL2019003049A1 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats. | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| DOP2021000229A (es) | Materiales y métodos para modular la inmunidad mediada por cédula t | |
| UY39011A (es) | Métodos para purificar cannabinoides, composiciones y kits de estos | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| GT200400076A (es) | Ligandos de receptores de cannabinoides y sus usos | |
| UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| UY30296A1 (es) | Compuestos fenil amido heterociclicos condensados | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| CO6640211A2 (es) | Composiciones del péptido a-beta y métodos | |
| CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| ECSP24032906A (es) | Compuestos y métodos dirigidos a la interleucina-34 | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств |